Search

Your search keyword '"Kedhi, E."' showing total 12 results
Start Over Author "Kedhi, E." Publisher springer science and business media llc
12 results on '"Kedhi, E."'

1. Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE trial

Author

Verdoia, M., primary, Suryapranata, H., additional, Damen, S., additional, Camaro, C., additional, Benit, E., additional, Barbieri, L., additional, Rasoul, S., additional, Liew, H. B., additional, Polad, J., additional, Ahmad, W. A. W., additional, Zambahari, R., additional, Lalmand, J., additional, van der Schaaf, R. J., additional, Koh, T. H., additional, Timmermans, P, additional, Dilling-Boer, D., additional, Veenstra, L. F., additional, van’t Hof, A. W. J., additional, Lee, S. W. L., additional, Roolvink, V., additional, Ligtenberg, E., additional, Postma, S., additional, Kolkman, E. J. J., additional, Brouwer, M. A., additional, Kedhi, E., additional, and De Luca, G., additional

Published
2021
Full Text
View/download PDF

4. The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study

Author

Hommels, T. M., primary, Hermanides, R. S., additional, Rasoul, S., additional, Berta, B., additional, IJsselmuiden, A. J. J., additional, Jessurun, G. A. J., additional, Benit, E., additional, Pereira, B., additional, De Luca, G., additional, and Kedhi, E., additional

Published
2019
Full Text
View/download PDF

5. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study

Author

Hommels, T. M., primary, Hermanides, R. S., additional, Rasoul, S., additional, Berta, B., additional, IJsselmuiden, A. J. J., additional, Jessurun, G. A. J., additional, Benit, E., additional, Pereira, B., additional, De Luca, G., additional, and Kedhi, E., additional

Published
2019
Full Text
View/download PDF

6. A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial

Author

Tavenier, A. H., primary, Hermanides, R. S., additional, Ottervanger, J. P., additional, Rasoul, S., additional, Slingerland, R. J., additional, Tolsma, R., additional, van Workum, S., additional, Kedhi, E., additional, and van ’t Hof, A. W. J., additional

Published
2019
Full Text
View/download PDF

7. Use, timing and outcome of coronary angiography in patients with high-risk non-ST-segment elevation acute coronary syndrome in daily clinical practice: insights from a ‘real world’ prospective registry

Author

Badings, E. A., primary, Hermanides, R. S., additional, Van Der Sluis, A., additional, Dambrink, J. H. E., additional, Gosselink, A. T. M., additional, Kedhi, E., additional, Ottervanger, J. P., additional, Roolvink, V., additional, Remkes, W. S., additional, van’t Riet, E., additional, Suryapranata, H., additional, and van’t Hof, A. W. J., additional

Published
2018
Full Text
View/download PDF

8. Appropriate use criteria for optical coherence tomography guidance in percutaneous coronary interventions

Author

IJsselmuiden, A. J. J., primary, Zwaan, E. M., additional, Oemrawsingh, R. M., additional, Bom, M. J., additional, Dankers, F. J. W. M., additional, de Boer, M. J., additional, Camaro, C., additional, van Geuns, R. J. M., additional, Daemen, J., additional, van der Heijden, D. J., additional, Jukema, J. W., additional, Kraaijeveld, A. O., additional, Meuwissen, M., additional, Schölzel, B. E., additional, Pundziute, G., additional, van der Harst, P., additional, van Ramshorst, J., additional, Dirksen, M. T., additional, Zivelonghi, C., additional, Agostoni, P., additional, van der Heyden, J. A. S., additional, Wykrzykowska, J. J., additional, Scholte, M. J., additional, Nef, H. M., additional, Kofflard, M. J. M., additional, van Royen, N., additional, Alings, M., additional, and Kedhi, E., additional

Published
2018
Full Text
View/download PDF

11. Treatment of Functional Mitral Regurgitation in Heart Failure

Author

Marco Masè, Renata Korcova, Serena Rakar, Antonio De Luca, Gianfranco Sinagra, Arnoud W J van 't Hof, Davide Stolfo, Andrea Perkan, Marco Merlo, Enrico Fabris, Elvin Kedhi, Giancarlo Vitrella, Fabris, E., De Luca, A., Vitrella, G., Stolfo, D., Mase, M., Korcova, R., Merlo, M., Rakar, S., van't Hof, A. W. J., Kedhi, E., Perkan, A., and Sinagra, G.

Subjects
Male, CLINICAL-OUTCOMES, medicine.medical_specialty, Percutaneous, IMPACT, medicine.medical_treatment, Heart team, Heart failure, Disease, 030204 cardiovascular system & hematology, Sacubitril, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Humans, MitraClip, Medicine, 030212 general & internal medicine, PREDICTORS, ANNULOPLASTY, EUROPEAN ASSOCIATION, Heart Valve Prosthesis Implantation, Mitral valve repair, CARDIOMYOPATHY, business.industry, Transcatheter interventions, Mitral Valve Insufficiency, Guideline, medicine.disease, PERCUTANEOUS REPAIR, Treatment Outcome, Valsartan, Functional mitral regurgitation, VALVE REPAIR, Cardiology, Mitral Valve, CARDIAC RESYNCHRONIZATION THERAPY, Female, Cardiology and Cardiovascular Medicine, business, NATIVE VALVULAR REGURGITATION, medicine.drug
Abstract

Purpose of Review: To analyze the current state of the art of functional mitral regurgitation (FMR) treatment. Recent Findings: The first-line treatment of severe FMR consists of guideline medical therapy (GMT) and resynchronization therapy when indicated; the impact of new medical therapies like sacubitril/valsartan needs further assessment. Valvular intervention may be considered in FMR symptomatic patients despite GMT, and can be performed surgically or percutaneously. MitraClip is a safe percutaneous procedure associated with symptoms improvement. Recently, the COAPT trial showed superior outcomes for MitraClip versus GMT contrasting the MITRA-FR trial which showed no benefit of MitraClip compared with GMT. These results should be interpreted as complementary rather than opposite. Summary: The COAPT trial provided a “proof of concept” that percutaneous treatment of severe FMR in patients without too advanced left ventricular disease translates into a prognostic benefit. Careful patient selection will play a critical role in defining the clinical niche for successful interventions.

Published
2019

12. Entrapment of dissection flap and intimal tissue cleavage during rotational atherectomy

Author

Elvin Kedhi, Jan Paul Ottervanger, Mark W. Kennedy, Enrico Fabris, Fabris, E., Kennedy, M., Kedhi, E., and Ottervanger, J. P.

Subjects
medicine.diagnostic_test, business.industry, Dissection, Complex PCI, Rotational atherectomy, Interventional radiology, General Medicine, Electronic Supplementary Material, Cleavage (embryo), Rotablator, Entrapment, Medicine, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, Nuclear medicine, business
Abstract

Electronic supplementary material The online version of this article ( https://doi.org/10.1007/s12928-018-0524-y ) contains supplementary material, which is available to authorized users.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results